YAP1 as a Novel Negative Biomarker of Immune Checkpoint Inhibitors for EGFR-Mutant Non-Small-Cell Lung Cancer

Figure 3

YAP1 is associated with poor prognosis of EGFR-mutant NSCLC patients. (a) The expression of YAP1 in the EGFR mutation group and EGFR-WT group. (b) The heatmap shows the differential expressions of YAP1 in the YAP1_High and YAP1_Low groups in EGFR-mutant NSCLC. (c-d) Kaplan–Meier analysis of the OS and PFS of the YAP1_High and YAP1_Low groups from TCGA LUAD. (e-f) Kaplan–Meier analysis of the OS of the two groups for GSE11969 and GSE72094.

(a)

(b)

(c)

(d)

(e)

(f)